Verastem Inc. Reports Q3 2026 Results and Announces Future Financing Plans
Verastem Inc. (NASDAQ: VSTM) released its third‑quarter 2026 financial results on November 5, 2026. The company reported revenue of $24.01 million, which missed analysts’ consensus by $2.07 million. Non‑GAAP earnings per share were –$0.72, falling short of the expected –$0.44 by $0.28. The earnings call transcript highlighted the company’s ongoing development activities and cash‑flow outlook.
Key Financial Highlights
| Metric | Q3 2026 | Forecast | Variance |
|---|---|---|---|
| Revenue | $24.01 M | $26.08 M | –$2.07 M |
| Non‑GAAP EPS | –$0.72 | –$0.44 | –$0.28 |
| Cash on Hand | Not disclosed | — | — |
| Debt | Not disclosed | — | — |
The results were summarized in a Yahoo Finance snapshot and a Finviz article, both noting that the company’s operating expenses were driven by clinical trial costs and corporate development activities.
Cash‑Flow Outlook
In a separate update posted the following day (November 6, 2026), Verastem confirmed that it expects an October 2026 financing round and additional co‑pack sales to fund operations through the first half of 2028. The company stated that the planned raise and revenue streams would provide sufficient liquidity to support its clinical pipeline and ongoing business operations.
A Finviz report highlighted that, despite a stall in co‑pack sales, the company’s VS‑7375 data and a planned $250 million raise are resetting the investment case. This aligns with the company’s stated goal of extending its cash runway to 2028.
Analyst Reaction
H.C. Wainwright, a research firm covering the biopharmaceutical sector, raised its price target for Verastem to $20 on November 6, 2026, citing progress in the company’s pipeline. The same upgrade was reported by both SeekingAlpha and German‑language investing.com outlets, indicating consensus among analysts that recent clinical data support an upward revision of the valuation.
Company Overview
Verastem is a development‑stage biopharmaceutical company headquartered in Needham, Massachusetts. Its focus is on medicines targeting RAF, MEK, and focal adhesion kinase (FAK) inhibition for cancer and tumor growth. The company is listed on Nasdaq and had a market capitalization of $1.14 billion as of the latest close. Its share price stood at $8.41 on November 5, 2026, with a 52‑week high of $10.82 (November 25, 2025) and a low of $3.43 (June 24, 2026). Verastem’s price‑earnings ratio is –4.15, reflecting its development‑stage status.
Summary
Verastem’s Q3 2026 earnings fell short of expectations, primarily due to lower than projected revenue and higher than anticipated costs. The company’s management has outlined a financing strategy that should extend its cash runway into the first half of 2028. Positive analyst coverage, particularly from H.C. Wainwright, reflects confidence in the company’s pipeline progress and the potential upside of the planned funding round.
